Muirhead N, Bargman J, Burgess E, Jindal K K, Levin A, Nolin L, Parfrey P
Department of Medicine, University of Western Ontario, London, Canada.
Am J Kidney Dis. 1995 Aug;26(2 Suppl 1):S1-24. doi: 10.1016/0272-6386(95)90645-2.
In an era of increasing scrutiny regarding use of health care resources, it is critical that physicians have rational, evidence-based guidelines for treatment decisions. This review of more than 200 published papers constitutes a comprehensive approach to evaluating the current evidence regarding the clinical use of recombinant human erythropoietin therapy in renal failure patients. After this review, specific recommendations are provided regarding who should receive r-HuEPO; what the target hemoglobin should be; the best route of administration of r-HuEPO; how iron status should be evaluated and managed; and monitoring and follow-up of patients taking r-HuEPO. Throughout the article, areas for important future research are also identified.
在一个对医疗资源使用审查日益严格的时代，医生拥有合理的、基于证据的治疗决策指南至关重要。这篇对200多篇已发表论文的综述构成了一种全面的方法，用于评估目前关于重组人促红细胞生成素疗法在肾衰竭患者临床应用的证据。经过此次综述，针对哪些患者应接受重组人促红细胞生成素治疗、目标血红蛋白应为多少、重组人促红细胞生成素的最佳给药途径、应如何评估和管理铁状态以及对接受重组人促红细胞生成素治疗的患者进行监测和随访等方面给出了具体建议。在整篇文章中，还确定了未来重要的研究领域。
